Amelioration of Sepsis by Macrophage Activation
Amelioration of Sepsis by Macrophage Activation
批准号:
7281703
负责人:
David L. Williams
金额:
$28.71万
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-04-01 至 2010-08-31
关键词:
1-Phosphatidylinositol 4-KinaseAbbreviationsAcuteAdult Respiratory Distress SyndromeApoptosisBasic ScienceBindingCarbohydratesCell ProliferationClassComplexCritical IllnessDataDevelopmentDiseaseEnzymesEventFamilyFeedbackGlucansGlycogenGoalsGrantHomeostasisHomologous GeneITAMITGAM geneImmune responseImmunocompetentInflammationInflammatoryInflammatory ResponseInjuryKnowledgeLigandsLigationLinkMacrophage ActivationMacrophage-1 AntigenMembraneMolecularMorbidity - disease rateMusMyelogenousNewborn Respiratory Distress SyndromeNuclearOutcomePDPK1 genePTEN genePathway interactionsPatientsPattern recognition receptorPhenotypePhosphatidylinositol 4,5-DiphosphatePhosphatidylinositolsPhosphotransferasesPhysiologicalPlayProto-Oncogene Proteins c-aktPuncture procedureRAC-Alpha Serine/Threonine KinaseReceptor SignalingReportingResearchResearch PersonnelResistanceRoleSR-A proteinsSepsisSepsis SyndromeSeptic ShockSignal PathwaySignal TransductionSplenocyteStreamSurface Plasmon ResonanceTNF receptor-associated factor 6TRAF6 geneToll-Like Receptor 2Toll-like receptorsTyrosinecytokinedectin 1improvedinositol-1,4,5-trisphosphate 5-phosphatasenovel therapeuticspreventreceptorresponsescavenger receptorseptictensintrafficking
中文摘要
描述(由申请人提供):危重患者经常出现复杂的疾病谱系,可能包括成人呼吸窘迫综合征(ARDS)、全身炎症反应综合征(SIRS)、败血症综合征和/或感染性休克。目前,我们还不了解脓毒性损伤发生和传播的细胞和分子机制;我们也不了解试图限制炎症、维持体内平衡和促进脓毒症患者生存的先天生理机制。磷脂内肽3-激酶/Akt (PI3K/Akt)是一个保守的信号转导酶家族,参与调节细胞增殖和存活。在上一个资助期间,我们发现信号转导酶PI3K家族通过限制增菌性败血症的炎症反应发挥重要的生理作用。具体来说,内源性PI3K抑制脓毒症宿主的促炎细胞因子释放和细胞凋亡。它还能促进暴发性败血症的生存。更重要的是,我们发现一种与膜相关模式识别受体结合的碳水化合物配体刺激PI3K/Akt通路,从而降低暴发性败血症的发病率和提高生存率。这些数据表明,刺激PI3K通路可能是预防和/或治疗脓毒症/感染性休克的有效方法。在目前的提案中,我们将扩展这些研究,以检查葡聚糖配体刺激PI3K/Akt信号传导的细胞和分子机制。我们将重点了解激活PI3K的配体-受体相互作用,刺激PI3K/Akt/GSK3的受体后信号转导事件,以及脓毒症损伤中PI3K调节和保护性表型诱导的细胞变化。这项研究的结果不仅会增加我们对炎性/感染性疾病先天反应的基础科学知识,而且还可能导致几种重要疾病状态的新治疗策略的发展。
英文摘要
DESCRIPTION (provided by applicant): The critically ill patient frequently develops a complex disease spectrum that may include adult respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS), sepsis syndrome and/or septic shock. At present, we do not understand the cellular and molecular mechanisms that are involved in the initiation and propagation of septic injury; nor do we understand the innate physiologic mechanisms that attempt to limit inflammation maintain homeostasis and promote survival in the septic patient. The phosphoinsitide 3-kinases/Akt (PI3K/Akt) is a conserved family of signal transduction enzymes which are involved in regulating cellular proliferation and survival. During the last grant period, we discovered that the PI3K family of signal transduction enzymes plays an important physiologic role by limiting the inflammatory response to plymicrobial sepsis. Specifically, endogenous PI3K suppresses pro-inflammatory cytokine release and apoptosis in the septic host. It also promotes survival in fulminating sepsis. Of greater significance, we discovered that a carbohydrate ligand that is bound by membrane associated pattern recognition receptors stimulates the PI3K/Akt pathway resulting in decreased morbidity and increased survival outcome in fulminating sepsis. These data suggest that stimulation of the PI3K pathway may be an effective approach for preventing and/or treating sepsis/septic shock. In the current proposal, we will extend these studies to examine the cellular and molecular mechanisms by which glucan ligands stimulate PI3K/Akt signaling. We will focus on understanding the ligand-receptor interactions that activate PI3K, the postreceptor signal transduction events that stimulate PI3K/Akt/GSK3 and the cellular changes that culminate in modulation of PI3K and induction of the protective phenotype in sepsis injury. Not only will the results of this research increase our basic science knowledge of the innate response to inflammatory/septic disease, but it may also result in the development of new treatment strategies for several important disease states.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of an alpha-1 phosphate mannan vaccine against the emerging fungal pathogen Candida auris.
-
批准号:10573467
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2023
-
负责人:David L. Williams
-
依托单位:
Amelioration of Sepsis by Macrophage Activation
-
批准号:7939064
-
项目类别:
-
资助金额:$11.5万
-
财政年份:2009
-
负责人:David L. Williams
-
依托单位:
Dietary supplementation with glucan enhances immune fn
-
批准号:6534558
-
项目类别:
-
资助金额:$15.56万
-
财政年份:2001
-
负责人:David L. Williams
-
依托单位:
IMMUNE RECOGNITION OF CANDIDA--ROLE OF CELL WALL
-
批准号:6225237
-
项目类别:
-
资助金额:$24.16万
-
财政年份:2001
-
负责人:David L. Williams
-
依托单位:
Dietary supplementation with glucan enhances immune fn
-
批准号:6317216
-
项目类别:
-
资助金额:$15.47万
-
财政年份:2001
-
负责人:David L. Williams
-
依托单位:
BIOMOLECULAR INTERACTION ANALYSIS INSTRUMENTATION
-
批准号:2489127
-
项目类别:
-
资助金额:$22.9万
-
财政年份:1998
-
负责人:David L. Williams
-
依托单位:
Amelioration of Sepsis by Macrophage Activation
-
批准号:8235529
-
项目类别:
-
资助金额:$28.71万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION
-
批准号:6628698
-
项目类别:
-
资助金额:$25.39万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION
-
批准号:2192894
-
项目类别:
-
资助金额:$15.38万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION
-
批准号:2685082
-
项目类别:
-
资助金额:$16.64万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
Amelioration of Sepsis by Macrophage Activation
-
批准号:7150183
-
项目类别:
-
资助金额:$29.57万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
Amelioration of Sepsis by Macrophage Activation
-
批准号:7679385
-
项目类别:
-
资助金额:$28.71万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION
-
批准号:6498428
-
项目类别:
-
资助金额:$25.39万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
Amelioration of Sepsis by Macrophage Activation
-
批准号:7497484
-
项目类别:
-
资助金额:$28.71万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION
-
批准号:6262619
-
项目类别:
-
资助金额:$25.04万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
Amelioration of Sepsis by Macrophage Activation
-
批准号:8400886
-
项目类别:
-
资助金额:$27.7万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION
-
批准号:6698553
-
项目类别:
-
资助金额:$25.39万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION
-
批准号:2392260
-
项目类别:
-
资助金额:$16.0万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION
-
批准号:2900857
-
项目类别:
-
资助金额:$17.3万
-
财政年份:1996
-
负责人:David L. Williams
-
依托单位:
海外基金